Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,936 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma.
Yang DH, Min JJ, Jeong YY, Ahn JS, Kim YK, Cho SH, Chung IJ, Bom HS, Kim HJ, Lee JJ. Yang DH, et al. Among authors: kim yk, kim hj. Ann Hematol. 2009 May;88(5):425-32. doi: 10.1007/s00277-008-0616-3. Epub 2008 Nov 12. Ann Hematol. 2009. PMID: 19002686 Clinical Trial.
Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
Ahn JS, Kim JY, Kim HJ, Kim YK, Lee SS, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Minden MD, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD. Ahn JS, et al. Among authors: kim jy, kim dd, kim hj, kim yk, kim sh, kim ny. Ann Hematol. 2016 Jan;95(2):301-10. doi: 10.1007/s00277-015-2540-7. Epub 2015 Nov 4. Ann Hematol. 2016. PMID: 26537612
Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
Ahn JS, Kim HJ, Kim YK, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD. Ahn JS, et al. Among authors: kim dd, kim hj, kim yk, kim sh, kim ny. Ann Hematol. 2016 Mar;95(4):625-35. doi: 10.1007/s00277-015-2580-z. Epub 2015 Dec 22. Ann Hematol. 2016. PMID: 26692090
Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study.
Kim YK, Sohn SK, Lee JH, Yang DH, Moon JH, Ahn JS, Kim HJ, Lee JJ; Korean Multiple Myeloma Working Party (KMMWP). Kim YK, et al. Among authors: kim hj. Ann Hematol. 2010 May;89(5):475-82. doi: 10.1007/s00277-009-0856-x. Epub 2009 Nov 18. Ann Hematol. 2010. PMID: 19921192 Clinical Trial.
5,936 results